"Promising Experimental Antibiotic Treatment for Lyme Disease Advances to Human Trials"
Northeastern professor Kim Lewis has developed a novel antibiotic treatment, hygromycin A, for Lyme disease, which is set to undergo human safety trials in Australia this spring. The treatment has shown promise in clearing Lyme in mice and is specifically targeted at spirochetes, the bacteria that transmits Lyme disease. If successful, the treatment could offer a more effective and less disruptive alternative to existing standard treatments, potentially reducing the number of chronic Lyme cases. If the safety trials are successful, the treatment could advance to phase 2 trials to determine effective dosing ranges and potential FDA approval.